eEF 2K—a new target in breast cancers with combined inactivation of p53 and PTEN

  • Russnes H
  • Caldas C
0Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Extensive efforts have now characterized the somatic molecular alterations in human breast cancer (Cancer Genome Atlas Network, 2012; Stephens et al, 2012) and have led to a re-definition of the disease as a constellation of 10 distinct driver-based subtypes (IntClust subtypes) (Curtis et al, 2012). The pursuit of druggable targets for each of these subtypes is now pressing. This is elegantly illustrated by the work of Liu et al (2014).

Cite

CITATION STYLE

APA

Russnes, H. G., & Caldas, C. (2014). eEF 2K—a new target in breast cancers with combined inactivation of p53 and PTEN . EMBO Molecular Medicine, 6(12), 1512–1514. https://doi.org/10.15252/emmm.201404683

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free